The latest CAR T cell therapies to be approved were Idecaptagene vivleucel and ciltacabtagene autoleucel in 2021 and early 2022, both targeting B cell maturation antigen (BCMA) to treat multiple myeloma. Here, TNFRSF17 is linked to plasma cell myeloma.